The comparative effects of statins, ezetimibe with or without statins and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors remain unassessed.
Design
Bayesian network meta-analysis was conducted to compare treatment groups.
Methods
Thirty-nine randomized controlled trials were selected using MEDLINE, EMBASE, and CENTRAL (inception – September 2017).
Results
In network meta-analysis of 189,116 patients, PCSK9 inhibitors were ranked as the best treatment for prevention of major adverse cardiovascular events (Surface Under Cumulative Ranking Curve (SUCRA), 85%), myocardial infarction (SUCRA, 84%) and stroke (SUCRA, 80%). PCSK9 inhibitors reduced the risk of major adverse cardiovascular events compared with ezetimibe + statin (odds ratio (OR): 0.72; 95% credible interval (CrI), 0.55–0.95; Grading of Recommendation Assessment, Development and Evaluation (GRADE) criteria: moderate), statin (OR: 0.78; 95% CrI: 0.62–0.97; GRADE: moderate) and placebo (OR: 0.63; 95% CrI: 0.49–0.79; GRADE: high). The PCSK9 inhibitors were consistently superior to groups for major adverse cardiovascular event reduction in secondary prevention trials (SUCRA, 95%). Statins had the highest probability of having lowest rates of all-cause mortality (SUCRA, 82%) and cardiovascular mortality (SUCRA, 84%). Compared with placebo, statins reduced the risk of all-cause mortality (OR: 0.88; 95% CrI: 0.83–0.94; GRADE: moderate) and cardiovascular mortality (OR: 0.84; 95% CrI: 0.77–0.90; GRADE: high). For cardiovascular mortality, PCSK9 inhibitors were ranked as the second best treatment (SUCRA, 78%) followed by ezetimibe + statin (SUCRA, 50%).
Conclusion
PCSK9 inhibitors were ranked as the most effective treatment for reducing major adverse cardiovascular events, myocardial infarction and stroke, without having major safety concerns. Statins were ranked as the most effective therapy for reducing mortality.
BartonPAndronisLBriggsAet al.Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: Modelling study. BMJ2011; 343: d0444–d0444.
2.
BaigentCKeechAKearneyPMet al.Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet2005; 366: 1267–1278.
3.
CannonCPBlazingMAGiuglianoRPet al.Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med2015; 372: 2387–2397.
4.
LipinskiMJBenedettoUEscarcegaROet al.The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: A network meta-analysis. Eur Heart J2016; 37: 536–545.
5.
TothPPWorthyGGandraSRet al.Systematic Review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia. J Am Heart Assoc2017, pp. 6–6.
6.
SabatineMSGiuglianoRPKeechACet al.Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med2017; 376: 1713–22.
7.
Cochrane Handbook for Systematic Reviews of Interventions. In: Higgins JP, Green S, eds.: The Cochrane Collaboration, 2011.
8.
HuttonBSalantiGCaldwellDMet al.The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann Intern Med2015; 162: 777–784.
9.
ShamseerLMoherDClarkeMet al.Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration & explanation. BMJ2015; 349: g7647–g7647.
10.
HigginsJPTAltmanDGGøtzschePCet al.The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ2011; 343: d5928–d5928.
11.
PuhanMASchunemannHJMuradMHet al.A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ2014; 349: g5630–g5630.
12.
BodnarOLinkAArendackaBet al.Bayesian estimation in random effects meta-analysis using a non-informative prior. Stat Med2017; 36: 378–399.
13.
LuGAdesAE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med2004; 23: 3105–3124.
14.
TurnerRMDaveyJClarkeMJet al.Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol2012; 41: 818–827.
15.
LarjoALähdesmäkiH. Using multi-step proposal distribution for improved MCMC convergence in Bayesian network structure learning. EURASIP J Bioinform Syst Biol2015; 2015: 6–6.
16.
SalantiGAdesAEIoannidisJP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial. J Clin Epidemiol2011; 64: 163–171.
17.
FarnierMJonesPSeveranceRet al.Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. Atherosclerosis2016; 244: 138–146.
18.
RothEMTaskinenMRGinsbergHNet al.Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial. Int J Cardiol2014; 176: 55–61.
19.
GinsbergHNRaderDJRaalFJet al.Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dl or Higher. Cardiovasc Drugs Ther2016; 30: 473–483.
20.
KasteleinJJGinsbergHNLangsletGet al.ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J2015; 36: 2996–3003.
21.
CannonCPCariouBBlomDet al.Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: The ODYSSEY COMBO II randomized controlled trial. Eur Heart J2015; 36: 1186–94.
22.
MoriartyPMThompsonPDCannonCPet al.Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol2015; 9: 758–769.
23.
BlomDJHalaTBologneseMet al.A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med2014; 370: 1809–1819.
24.
KouvelosGNArnaoutoglouEMMatsagkasMIet al.Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: Results of a pilot study. J Cardiovasc Pharmacol Ther2013; 18: 5–12.
25.
BaigentCLandrayMJReithCet al.The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet2011; 377: 2181–2192.
26.
FellstromBCJardineAGSchmiederREet al.Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med2009; 360: 1395–1407.
27.
RidkerPMDanielsonEFonsecaFAet al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med2008; 359: 2195–2207.
28.
RosseboABPedersenTRBomanKet al.Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med2008; 359: 1343–1356.
29.
CrouseJR3rdRaichlenJSRileyWAet al.Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: The METEOR Trial. JAMA2007; 297: 1344–1353.
30.
KjekshusJApetreiEBarriosVet al.Rosuvastatin in older patients with systolic heart failure. N Engl J Med2007; 357: 2248–2261.
31.
LandrayMBaigentCLeaperCet al.The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: A randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis2006; 47: 385–395.
32.
AmarencoPBogousslavskyJCallahanA3rdet al.Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Eng J Med2006; 355: 549–559.
33.
KnoppRHd’EmdenMSmildeJGet al.Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care2006; 29: 1478–1485.
34.
ColhounHMBetteridgeDJDurringtonPNet al.Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet2004; 364: 685–696.
35.
HoldaasHFellstromBJardineAGet al.Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet2003; 361: 2024–2031.
36.
ShepherdJBlauwGJMurphyMBet al.Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet2002; 360: 1623–1630.
37.
BradfordRHDowntonMChremosANet al.Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia. Ann Intern Med1993; 118: 850–855.
38.
PedersenTRKjekshusJBergKet al.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl2004; 5: 81–87.
39.
ShepherdJCobbeSMFordIet al.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med1995; 333: 1301–1307.
40.
SacksFMPfefferMAMoyeLAet al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med1996; 335: 1001–1009.
41.
DownsJRClearfieldMWeisSet al.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA1998; 279: 1615–1622.
42.
Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med1998; 339: 1349–1357.
43.
SerruysPWde FeyterPMacayaCet al.Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA2002; 287: 3215–3222.
44.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet2002; 360: 7–22.
45.
KorenMJHunninghakeDB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: The Alliance study. J Am Coll Cardiol2004; 44: 1772–1779.
46.
TavazziLMaggioniAPMarchioliRet al.Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet2008; 372: 1231–1239.
47.
KereiakesDJRobinsonJGCannonCPet al.Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Am Heart J2015; 169: 906–915.e13.
48.
SabatineMSGiuglianoRPWiviottSDet al.Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med2015; 372: 1500–1509.
49.
RothEMMoriartyPMBergeronJet al.A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. Atherosclerosis2016; 254: 254–262.
50.
StroesEGuytonJRLeporNet al.Efficacy and safety of alirocumab 150 mg every 4 weeks in patients with hypercholesterolemia not on statin therapy: The ODYSSEY CHOICE II Study. J Am Heart Assoc2016, pp. 5–5.
51.
YusufSBoschJDagenaisGet al.Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med2016; 374: 2021–2031.
52.
SilvermanMGFerenceBAImKet al.Association between lowering ldl-c and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis. JAMA2016; 316: 1289–1297.
53.
CatapanoALGrahamIDe BackerGet al.2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J2016; 37: 2999–3058.
54.
StoneNJRobinsonJGLichtensteinAHet al.2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol2014; 63: 2889–2934.
55.
KhanARBavishiCRiazHet al.Increased risk of adverse neurocognitive outcomes with proprotein convertase subtilisin-kexin type 9 inhibitors. Circ Cardiovasc Qual Outcomes2017, pp. 10–10.
56.
GiuglianoRPMachFZavitzKet al.Cognitive function in a randomized trial of evolocumab. N Engl J Med2017; 377: 633–643.
57.
SchmidtAFPearceLSWilkinsJTet al.PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev2017; 4: Cd011748–Cd011748.
58.
KaziDSPenkoJCoxsonPGet al.Updated cost-effectiveness analysis of pcsk9 inhibitors based on the results of the fourier trial. JAMA2017; 318: 748–750.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
